Category Press Releases

Ionis Reports Encouraging Findings from Phase 2 Trial of ION224, Showing Clinical Effectiveness in NASH/MASH Treatment

Ionis has unveiled encouraging outcomes from its Phase 2 investigation of ION224, a DGAT2 antisense inhibitor aimed at addressing metabolic dysfunction-associated steatohepatitis (MASH), previously termed nonalcoholic steatohepatitis (NASH). The study, encompassing 160 patients over 51 weeks, successfully met its primary…

Read MoreIonis Reports Encouraging Findings from Phase 2 Trial of ION224, Showing Clinical Effectiveness in NASH/MASH Treatment

Wegovy® Approved in US to Lower Cardiovascular Risk in Overweight or Obese Individuals with Existing Heart Conditions

Novo Nordisk has announced today that the US Food and Drug Administration (FDA) has granted approval for an expanded label for Wegovy®. This approval, based on a supplemental New Drug Application (sNDA), extends the indication of Wegovy® to include the…

Read MoreWegovy® Approved in US to Lower Cardiovascular Risk in Overweight or Obese Individuals with Existing Heart Conditions

Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants

Vivani Medical, Inc. (Nasdaq: VANI), a pioneering biopharmaceutical company in the preclinical stage, has recently announced a significant move towards advancing its innovative long-term drug implants. In a registered direct offering, the company has entered into a securities purchase agreement…

Read MoreVivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants

Shionogi and Osaka University Establish a New Joint Research Lab on Post-COVID-19 Condition (Long COVID)

Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced that Shionogi and Osaka University (Location: Suita, Osaka, President: Shojiro Nishio) have established a joint research laboratory (research lab’s name: Joint Research Laboratory…

Read MoreShionogi and Osaka University Establish a New Joint Research Lab on Post-COVID-19 Condition (Long COVID)

FDA Prioritizes Review of EPKINLY® for Tough Follicular Lymphoma Cases

AbbVie (NYSE: ABBV) announces today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the supplemental Biologics License Application (sBLA) concerning epcoritamab-bysp, a subcutaneously administered T-cell engaging bispecific antibody. This treatment targets adult patients with relapsed…

Read MoreFDA Prioritizes Review of EPKINLY® for Tough Follicular Lymphoma Cases

FDA Prioritizes Review of Dupixent® sable for COPD Treatment Targeting Type 2 Inflammation

The U.S. Food and Drug Administration (FDA) has given priority review status to the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab), marking its sixth potential indication. This review targets its use as an add-on maintenance treatment for specific adult…

Read MoreFDA Prioritizes Review of Dupixent® sable for COPD Treatment Targeting Type 2 Inflammation